EMD Millipore Expands Cell Analysis Portfolio with Amnis Buy | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – EMD Millipore today announced that it has signed an agreement to acquire Seattle-based Amnis, a developer and manufacturer of high-speed cellular imaging instruments.

Amnis' technology is used for flow cytometry applications in academic, biotech, and pharmaceutical cell analysis and research. The acquisition complements EMD Millipore's existing Guava product offerings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.